Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Company Overview

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases. The programs are being developed initially for conditions such as plaque psoriasis, with potential applications in other immune-mediated disorders.

Oruka became a publicly traded company through a business combination with ARCA biopharma, Inc. in 2024, after which ARCA adopted the Oruka Therapeutics name and its shares began trading under the ORKA symbol. The company is focused on advancing its pipeline through clinical development and regulatory processes for patients in the United States and potentially other markets.

Key Stats

• Today's Range: $81.83 to $85.23
• 50-Day Range: $82.15 to $113.08
• 52-Week Range: $19.74 to $115.51
• Volume: 629,589 shs
• Average Volume: 968,060 shs
• Market Capitalization: $5.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $128.91
• Consensus Rating: Moderate Buy

Oruka Therapeutics Stock Analysis - MarketRank™

Oruka Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 356th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oruka Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oruka Therapeutics has a consensus price target of $128.91, representing about 52.8% upside from its current price of $84.38.

Amount of Analyst Coverage

Oruka Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oruka Therapeutics are expected to decrease in the coming year, from ($2.42) to ($2.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oruka Therapeutics is -41.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oruka Therapeutics is -41.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oruka Therapeutics has a P/B Ratio of 8.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.05% of the float of Oruka Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oruka Therapeutics has a short interest ratio ("days to cover") of 11.61, which indicates bearish sentiment.

Change versus previous month

Short interest in Oruka Therapeutics has recently decreased by 2.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oruka Therapeutics does not currently pay a dividend.

Dividend Growth

Oruka Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Oruka Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Oruka Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for ORKA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oruka Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,619,306.00 in company stock.

Percentage Held by Insiders

23.49% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORKA
• Previous Symbol: NASDAQ:ORKA
• CIK: 907654
• Web: www.orukatx.com
• Phone: (650) 606-7910
• Fax: 720-208-9261
• Employees: 68
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oruka Therapeutics: $128.91
• High Price Target: $200.00
• Low Price Target: $45.00
• Potential Upside/Downside: +52.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.65%
• Return on Assets: -20.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 38.51
• Quick Ratio: 38.51

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.69 per share
• Price / Book: 8.71

Miscellaneous

• Outstanding Shares: 66,210,000
• Free Float: 50,657,000
• Market Cap: $5.59 billion
• Optionable: N/A
• Beta: -0.37